Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naïve Follicular Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Follicular Lymphoma
- Small Lymphocytic Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The study will assess the safety and efficacy of umbralisib in combination with ublituximab in subjects with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL). Ublituximab will be administered through Cycle 12, while umbralisib will be administered through cycle 24. After...
The study will assess the safety and efficacy of umbralisib in combination with ublituximab in subjects with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL). Ublituximab will be administered through Cycle 12, while umbralisib will be administered through cycle 24. After this time, subjects will be followed for PFS.
Tracking Information
- NCT #
- NCT03828448
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon